<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>MerciaPharma</title>
	<atom:link href="http://merciapharma.com/?feed=rss2" rel="self" type="application/rss+xml" />
	<link>http://merciapharma.com</link>
	<description>&#34;Developing Safe and Efficacious Disease-Specific Immunotherapeutics&#34;</description>
	<lastBuildDate>Sun, 14 Nov 2010 04:45:50 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0.1</generator>
		<item>
		<title>Mercia Licenses Vaccine Stabilization Technology from Nova</title>
		<link>http://merciapharma.com/?p=325</link>
		<comments>http://merciapharma.com/?p=325#comments</comments>
		<pubDate>Wed, 29 Sep 2010 02:53:27 +0000</pubDate>
		<dc:creator>David Brush</dc:creator>
				<category><![CDATA[NEWS: Mercia Licenses Vaccine Stabilization Technology from Nova]]></category>
		<category><![CDATA[NEWS]]></category>

		<guid isPermaLink="false">http://69.89.31.115/~merciaph/?p=325</guid>
		<description><![CDATA[Mercia Pharma Inc., NY, has obtained a worldwide license from Nova Laboratories Limited, UK to a proprietary Trehalose glass protein stabilization technology for use in Mercia’s vaccines.  This technology uniquely allows proteins to be stabilized in a spray-dried formulation while maintaining full activity over extended periods at room temperature or above. Peter Blackburn, President of <a href='http://merciapharma.com/?p=325'>[...]</a>]]></description>
			<content:encoded><![CDATA[<p>Mercia Pharma Inc., NY, has obtained a worldwide license from Nova Laboratories Limited, UK to a proprietary Trehalose glass protein stabilization technology for use in Mercia’s vaccines.  This technology uniquely allows proteins to be stabilized in a spray-dried formulation while maintaining full activity over extended periods at room temperature or above. Peter Blackburn, President of Mercia, stated, “ We have a strong relationship with Nova. Mercia previously entered into a partnership with Nova that gives Mercia full manufacturing capabilities for our products without having to build infrastructure.  Now we have entered a new phase of our relationship whereby Mercia has gained access to complementary technology that synergizes with our <strong>MERIT</strong> platform.&#8221;  As part of the transaction, Nova acquired an equity stake in Mercia.</p>
]]></content:encoded>
			<wfw:commentRss>http://merciapharma.com/?feed=rss2&amp;p=325</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

